Analysts Offer Predictions for Atossa Genetics Q1 Earnings

Atossa Genetics Inc. (NASDAQ:ATOS) – Equities research analysts at Ascendiant Capital Markets issued their Q1 2027 earnings per share estimates for shares of Atossa Genetics in a research note issued to investors on Thursday, April 9th. Ascendiant Capital Markets analyst E. Woo expects that the company will post earnings per share of ($1.10) for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Atossa Genetics’ current full-year earnings is ($0.22) per share. Ascendiant Capital Markets also issued estimates for Atossa Genetics’ Q2 2027 earnings at ($1.10) EPS, Q3 2027 earnings at ($1.09) EPS and Q4 2027 earnings at ($1.09) EPS.

Several other equities analysts have also commented on ATOS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. HC Wainwright lifted their price target on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a report on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $36.33.

Atossa Genetics Price Performance

Shares of ATOS stock opened at $5.35 on Tuesday. The firm’s 50-day simple moving average is $4.83 and its 200-day simple moving average is $9.27. Atossa Genetics has a 1-year low of $3.76 and a 1-year high of $19.35. The firm has a market cap of $46.06 million, a P/E ratio of -1.49 and a beta of 1.34.

Hedge Funds Weigh In On Atossa Genetics

Large investors have recently modified their holdings of the company. Ameriprise Financial Inc. purchased a new stake in shares of Atossa Genetics during the 2nd quarter worth about $2,468,000. Renaissance Technologies LLC raised its holdings in Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after buying an additional 514,175 shares during the period. Jane Street Group LLC acquired a new position in Atossa Genetics during the second quarter valued at approximately $381,000. Qube Research & Technologies Ltd lifted its position in Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after buying an additional 325,340 shares in the last quarter. Finally, GSA Capital Partners LLP grew its stake in Atossa Genetics by 509.0% during the third quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock worth $269,000 after buying an additional 259,725 shares during the period. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.